Vyleesi and the FDA approval — what the trials showed

It was a real milestone. The honest accounting of what the trials showed — and what they didn't — is more complicated than the headline.

The pivotal program was called RECONNECT. Two parallel Phase III randomized controlled trials enrolled premenopausal women aged 21 to 55 with acquired, generalized hypoactive sexual desire disorder — meaning HSDD that had developed after a period of normal function (not lifelong), and that occurred across most sexual situations (not situationally). This distinction in the diagnostic criteria matters. HSDD is not simply lower-than-average desire. It's clinically significant low desire that causes personal distress. The distress criterion was built into the enrollment criteria, and it was built into the primary endpoints, for a reason: many women with below-average desire are not distressed by it. The population of clinical interest is the one for whom the absence of desire is experienced as a loss, as something wrong, as a problem they want solved.

The primary endpoints were two: change from baseline in sexual desire as measured by the Female Sexual Function Index desire domain score, and change in distress as measured by the Female Sexual Distress Scale — Desire/Arousal/Orgasm subscale. Both endpoints required statistically significant improvement for approval. Both were met. But the word "statistically significant" does a lot of quiet work here that deserves unpacking.

In the RECONNECT trials, women in the bremelanotide arms showed a mean increase in the FSFI desire domain score of approximately 0.5 points relative to placebo on a scale ranging from 1.2 to 6. The FSDS distress score showed a mean decrease of roughly 4 points on a 0–52 scale, compared to a smaller placebo decrease. These differences were real — they were reproducible across two trials, which is why the FDA accepted them — but they were not large. A clinician looking at them honestly would say: some patients experienced meaningful benefit; the average benefit across the treated population was modest; and the effect size was smaller than most people imagine when they hear that a drug was FDA-approved.

This is not unusual. Psychiatric and psychosexual pharmacology routinely operates with effect sizes that would seem modest in other disease categories. The relevant comparator isn't a perfectly effective drug — there is no perfectly effective drug for desire. The relevant comparator is what existed before: which was, in women with acquired generalized HSDD, essentially nothing other than flibanserin, off-label testosterone, and therapy.

The dosing protocol that was approved tells part of the story about why Vyleesi has struggled commercially. The recommended dose is 1.75 mg administered subcutaneously — by injection, self-administered — approximately 45 minutes before anticipated sexual activity. This is on-demand dosing: not a daily pill, not a patch, not a ring, but a prefilled autoinjector you use in the abdomen or thigh roughly an hour before the occasion. For some patients this is a practical solution; for many, it's a significant friction. Sexual activity, especially in the context of a desire disorder where spontaneity is already compromised, is not always anticipated 45 minutes in advance. The timing requirement introduces a planning element that sits awkwardly against what the drug is supposed to restore.

The adverse effect profile was the other commercial problem. Nausea was the dominant adverse event in both trials, occurring in approximately 40% of bremelanotide-treated women — a substantial fraction. For some, it was manageable; for others, it was severe enough to discontinue. The nausea typically began within an hour of injection and resolved within a few hours, but the combination of a subcutaneous injection, planned timing, and the near-certain prospect of nausea afterward was enough to make the on-label experience significantly less appealing than the clinical trial data alone might suggest.

Transient blood pressure elevation was the other safety finding that carried into labeling. Bremelanotide causes mean increases in systolic blood pressure of approximately 2–4 mmHg, with some individuals experiencing larger increases. The blood pressure elevation is transient — peaking around 4–12 hours and resolving within 12 hours — but it's consistent enough that the drug is contraindicated in people with existing cardiovascular or cerebrovascular disease, and it required a REMS program (a Risk Evaluation and Mitigation Strategy) at the time of approval, though this was later removed as the postmarket cardiovascular risk picture became clearer.

Hyperpigmentation — darkening of skin, gums, or breast tissue — was observed in approximately 1% of patients in the trials with repeated use. This is a direct consequence of MC1R activation, the same receptor pathway that Melanotan II was designed to exploit for tanning. PT-141 was developed to minimize MC1R activity relative to MC4R, and it largely does; but at clinical doses over repeated administrations, some degree of melanin pathway stimulation is measurable. For most patients this is cosmetically minor. For patients with darker skin tones, it may be more noticeable and less acceptable.

The RECONNECT program deliberately enrolled only premenopausal women. This is the population in which Vyleesi is approved. The decision was scientifically and regulatorily defensible — hormonal context changes substantially at menopause, and studies in premenopausal and postmenopausal populations would require separate analysis — but it leaves a significant population without approved options. Postmenopausal women with HSDD are a large group, and there is no approved version of bremelanotide for them. This is not because the mechanism is presumed to be ineffective in that population — it's because no trials were conducted.

Commercially, Vyleesi has not performed well. Palatin Technologies licensed the drug to AMAG Pharmaceuticals and, following AMAG's acquisition by Covis Pharma, the commercial rollout has been limited by the very factors the trials disclosed: modest effect, subcutaneous delivery, nausea burden, and a patient population that has historically been undertreated and under-educated about the fact that a pharmacological option now exists for their diagnosis. Physician prescribing has been constrained by lack of familiarity with the diagnosis of HSDD, discomfort discussing female sexual desire in clinical settings, and limited marketing compared to the PDE5 inhibitor category, which had pharmaceutical marketing machines behind it from launch.

None of these commercial realities change the underlying pharmacology. The mechanism — MC4R agonism producing central dopaminergic and oxytocinergic arousal — is real, and the trials demonstrated that for some women, it produces meaningful improvement. The question for clinical practice is less whether bremelanotide works and more for which patients the benefit is large enough to justify the delivery method and side effect profile. That's a question that requires an individual conversation with a prescribing provider who can evaluate desire, distress, hormonal status, relationship context, and medical history — not a formula applied uniformly.

What the RECONNECT trials established, permanently, is that female hypoactive sexual desire disorder is a clinical entity that responds to pharmacological intervention — specifically to central MC4R agonism — in a way that can be measured, reproduced, and approved by a rigorous regulatory agency. That's a scientific statement that persists independent of commercial performance. The compound may be imperfect. The delivery may need refinement. The effect sizes may be modest. But the door that the trials opened — the proof that desire is addressable pharmacologically, centrally, in women, through a pathway that doesn't run through hormones or blood vessels — is not the kind of door that closes.